AI assistant
Cocrystal Pharma, Inc. — Director's Dealing 2015
Mar 5, 2015
35066_dirs_2015-03-05_bc08cc13-e750-418b-9d94-f6951a2a54e5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2015-03-03
Reporting Person: Lee Sam (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-03-03 | Common Stock | M | 15287847 | — | Acquired | 15287847 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-03-03 | Series B Preferred Stock | $ | M | 74545 | Disposed | Common Stock (15287847) | Direct |
Footnotes
F1: Each share of Series B Convertible Preferred Stock held by the reporting person was automatically convertible for no additional consideration into 205.08308640 shares of the issuer's common stock at such time as the issuer obtained sufficient authorized capital. The issuer filed a charter amendment increasing its authorized common stock with the Secretary of State of Delaware on March 3, 2015, which caused the automatic conversion of the Series B Convertible Preferred Stock into common stock. The Series B Convertible Preferred Stock had no expiration date.